CA2378987C - A binder for pharmaceutical compositions - Google Patents
A binder for pharmaceutical compositions Download PDFInfo
- Publication number
- CA2378987C CA2378987C CA002378987A CA2378987A CA2378987C CA 2378987 C CA2378987 C CA 2378987C CA 002378987 A CA002378987 A CA 002378987A CA 2378987 A CA2378987 A CA 2378987A CA 2378987 C CA2378987 C CA 2378987C
- Authority
- CA
- Canada
- Prior art keywords
- binder
- pharmaceutical composition
- active ingredient
- echinacea extract
- echinacea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Pharmaceutical compositions, which contain a binder that comprises a binding-effective amount of Echinacea preparation are described.
Description
A BINDER FOR PHARMACEUTICAL COMPOSITIONS
FIELD OF THE INVENTION
The present invention is generally in the field of pharmaceutics and concerns a pharmaceutical composition comprising an active ingredient and a binder holding together the constituents of the composition.
BACKGROUND OF THE INVENTION AND PRIOR ART
Pharmaceutical compositions typically consist of at least one active ingredient and several excipients. The excipients may be disintegrants, which assist in releasing the active ingredient under the desired conditions, lubricants, which improve ejection from machine tooling, glidents, which improve flow, binders, i o which bind together different ingredients of the composition, etc.
Binders are of special importance in solid dosage forms, like tablets, pellets, microgranules, and sachets, where they are essential for holding together several different solid ingredients.
Pharmaceutically acceptable binders that are in wide use include, for example: starch, starch derivatives, polyvinilpyrolidone (PVP), alginate derivatives, and glucose.
Echinacea is well known as a food additive, and as such is known to be safe for consumption. It was also proposed as a pharmaceutically active ingredient, and the British Herbal Pharmacopeia (1996) defmes it as an immunostimulant.
Derwent Abstract No. 012237708 describes a drug that comprises paracetamol, caffeine, Echinacea and several other ingredients for use as an analgesic. Derwent Abstract No. 012234518 describes a cold treatment agent that comprises Echinacea and antipyretic and anti-inflammatory agent.
FIELD OF THE INVENTION
The present invention is generally in the field of pharmaceutics and concerns a pharmaceutical composition comprising an active ingredient and a binder holding together the constituents of the composition.
BACKGROUND OF THE INVENTION AND PRIOR ART
Pharmaceutical compositions typically consist of at least one active ingredient and several excipients. The excipients may be disintegrants, which assist in releasing the active ingredient under the desired conditions, lubricants, which improve ejection from machine tooling, glidents, which improve flow, binders, i o which bind together different ingredients of the composition, etc.
Binders are of special importance in solid dosage forms, like tablets, pellets, microgranules, and sachets, where they are essential for holding together several different solid ingredients.
Pharmaceutically acceptable binders that are in wide use include, for example: starch, starch derivatives, polyvinilpyrolidone (PVP), alginate derivatives, and glucose.
Echinacea is well known as a food additive, and as such is known to be safe for consumption. It was also proposed as a pharmaceutically active ingredient, and the British Herbal Pharmacopeia (1996) defmes it as an immunostimulant.
Derwent Abstract No. 012237708 describes a drug that comprises paracetamol, caffeine, Echinacea and several other ingredients for use as an analgesic. Derwent Abstract No. 012234518 describes a cold treatment agent that comprises Echinacea and antipyretic and anti-inflammatory agent.
GEt TERAL DESCRIPTIOi~ OF THE IIYViEi'iTION
In accordance with the invention powder or extract of Echinacea is used as a binder in solid pharrnaceutiacal compositions, e.g. compositions in the form of tablets, pellets, capsules, microgranules, powders, etc.
Echinacea powder or extract (hereiafter Echfnacea preparation) may be obtained from Echinacea leafes, roots, or whole plants. Examples of Echinacea species that preparations thereof are suitable to serve as binders according to the present invention are those known as Ecl;inacea purpurea, Echinacea angustlfolia, Echinacea pallida, Echinacea paradoxa, Echinacea tennesseensis, Echinacea 1 o sanguinea, Echinacea simulata and Echinacea atrotubens.
Examples of Echinacea preparations are Echinacea angustifoliae herba et radix, Echinacea pallidae herba, Echinacea pallidae radix, Echir..acea purpureae herba, and Echinacea pwpareae redrr.
Thus, the present invention provides, by a first of its aspects, a ls pharlnaceutical composition comprising particulate matter containing at least one pharmaceutically active ingredient and a binder, characterized in that said binder comprises a binding-effective amount of Echinacea preparation.
The term "binding-effectfve amount" should be understood to denote an amount of Echinacea preparation effective in binding or assisting in binding 20 together components of the composition. The binder may consist of Echinacea preparation or may be a mixture of Echinacea preparation and other ingredients, with the Echinacea preparation having a role in binding the compositions' component together. The property of being included in a binding-effective amount is manifested in that when the Echinacea preparation is removed, the composition's 25 other components will not bind to one another at sufficient strength to hold the composition's components together. In the presence of a binding-effective amount of Echinacea preparation, there is a measurable improvement of physical properties such as hardness (in tablets) and of flowability (in powders) in comparison to the same tablets or powders in the absence of binding-effective amount of Echinacea 30 preparation. Typically, the Echinacea preparation will constitute at least about 20 wt%
_ j -of the binding component of the composition, preferably at least about 40 wt%, and particularly preferably at least about 60 wt% and desirably above 80 wt%
of the binding component of the composition The pharmaceutical composition is typically formed into a dosage form such as a tablet or a capsule. At times, the formed pharmaceutical=composition, e.g. h-i the form of small pellets, powder, and the like, may be incorporated into a capsule or a sachet.
The active ingredient may be an analgesic, an antipyretic agent, an anti-inflammatory agent, a vitamin, an expectorant, an antibiotic, etc. These types io of active ingredients are but an example and the invention is not limited thereto. On the contrary, the pharmaceutical compositions of the invention may be used for essentially all types of different active ingredients, which are compatible with the Echinacea preparation. Furthermore, the pharmaceutical composition of the invention is intended for oral administration and thus the active ingredient should be adapted for such form of administration, namely, should be orally bioavailable.
Specific examples of active ingredients are paracetamol, carbocysteine, dextromethorphan, loratadine and vitamin C.
The invention also provides, by another of its aspects, a process for forming a phannaceutical composition, comprising:
(a) preparing a mixture comprising at least one active ingredient and an excipient;
(b) adding a binder to said mixture; and (c) processing said mixture to yield an administration forni, in which form said binder binds together ingredients of the composition;
said process being characterized in that said binder comprises a binding-effective amount of Echinacea preparation and said processing comprises applying conditions in which said preparation binds together ingredients of the composition.
By a still ftwther aspect, the present invention provides a method of administering Echinacea preparation and a pharinaceutically active ingredient to an ;o individual, comprising:
(a) preparing a mixture comprising said active ingredient, an excipient and the Echinacea preparation;
(b) processing the mixture to obtain an administration form, said processing being under conditions such that said preparation bind together all the ingredients in the administration form;
(c) administering said administration form to the individual.
The invention even further provides use of an excipient of Echinacea preparation and an active ingredient to yield a pharmaceutical composition wherein said preparation binds together components of the composition.
In accordance with one aspect of the present invention there is provided a pharmaceutical composition comprising: at least one pharmaceutically active ingredient and at least one excipient, said at least one excipient includes a binder, said binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, and said binder is mixed with the at least one pharmaceutically active ingredient of the composition, to form a solid pharmaceutical composition form wherein the Echinacea extract is blended with said at least one pharmaceutically active ingredient and said pharmaceutical composition is in a solid form adapted for administration.
In accordance with another aspect of the present invention there is provided a process for forming a pharmaceutical composition comprising at least one pharmaceutically active ingredient and at least one excipient, wherein said excipient includes a binder; the process comprising mixing said at least one pharmaceutically active ingredient with said binder, wherein said binder comprises at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, to obtain a blend of said at least one pharmaceutically active ingredient and Echinacea extract; and processing the blend to produce the pharmaceutical composition in a solid form adapted for administration.
In accordance with yet another aspect of the present invention there is provided in a method for producing a pharmaceutical composition in tablet form, an improved method for obtaining harder tablets, the improvement comprising: adding to a 4a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
In accordance with a further aspect of the present invention there is in a method for producing a pharmaceutical composition in powder form, an improved method for obtaining powder with improved flowability, the improvement comprising: adding to a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
In accordance with yet a further aspect of the present invention there is provided an Echinacea extract as a binder for a pharmaceutical composition, wherein said binder comprises at least 2 wt.% of Echinacea extract of said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder.
In accordance with still a further aspect of the present invention there is provided a use of an Echinacea extract as a binder in the manufacture of a pharmaceutical composition, wherein said binder comprises at least 2 wt.% of Echinacea extract of said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder.
The invention will now be illustrated in the following non-lirniting examples.
In accordance with one embodiment of the present invention there is an Echinacea extract as a binder for a pharmaceutical composition.
In accordance with another embodiment of the present invention there is use of an Echinacea extract as a binder in the manufacture of a pharmaceutical composition.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. I shows the size distribution of the particles obtained in example 1.
Fig. 2 shows the size distribution of the particles obtained in example 2.
4b EXAMPLES
In the following example 1 the Echinacea preparation was Echinacea purpurea E, supplied by Phannabeta AG, Switzerland and in examples 2, 3, and 4 the Echinacea preparation was Echinacea Plante Extrait Sec supplied by Martin Bower, France.
Example 1: Preparation of Paracetamol tablets with Echinacea as a single binder.
11.6 g of Echinacea were dissolved in 60 ml of purified water and the solution was poured drop-wise on 215 g of paracetamol and mixed with it manually. The mixture was dried in 45 C (LOD=1.0%). The resulting dry granulate was ground in a 1 mm net. 1 g magnesium stearate and 9.0 g of PrimojeP' were added. The mixture was moistured with a little water and dried (LOD=2.8%). The dried mixture was then pressed to give round tablets of 13 mm diameter, each e I de I. I I I i i x. 1 WO G 3!jfil 4 11 -5 PLTiiL ,r.'Ui;D41s -J-containing 500 mg of paracetamol. The hardness of the tabiets was 44 5 N. The size distribution of the resulting pal -ticles is shown in Figure 1.
Example 2: Preparation of carboeysteiu capsules wlt3n Echinacea as a single binder.
5 g of Echinacea preparation were dissolved in 30 ml water.
187.5 g of carbocystein were mixed with 4 g of AvicelTM
The Echinacea solution was ad,ded to the mixture of the powders and I o manually stirred to granulation. 'I'hegranulate was dried at 40 C
(L{}I3=0.7%). The dry granulate was ground on a 1 mm net and mixed with 7 g AvicelT and 1 g magnesium stearate to give the final blend. The final blend was filled inside hard gelatin capsules of capsule size no. 0, 375 mg active ingredient per capsule.
The particle size distribution of the final blend is shown in Figure 2.
Example 3: Application of dextromethorphan on peRets, using Echinacea as a binder.
8 g of Echinacea were dissolved in 300 ml of purified water, and 4 g of PEG 4000 were added to the solution. 40 g of dextromethorphan HBr were added to the solution to give a dispersion. The dispersion was applied to Neutral pellets No. 20 during heating. 40 g of dextromethyorphan IHBr were suspended in tge alm solution and sprayed on neutral sugar sphere (pellets size 20) using Glatt-Wurster equipment. Coated pelletswere filled inside hard gelatin capsules.
Example 4: Preparation of Loratadine tablets by direct compression with Echirracesa.
10 g of Loratadine were mixed with 25 g of Echinacea. The mixture was 3o sieved on a 50 mesh sieNie. 163 g of Lactose DC were added and mixed. 2 g of magnesium stearate were added and mixed to give the fmal mixture. The final mixture was pressed in a die to give tablets that contained 100 mg and 200 mg active ingredient. The 100 mg tablets had hardness of 99 1 N and the 200 mg tablets had hardness of 85 1 N.
In accordance with the invention powder or extract of Echinacea is used as a binder in solid pharrnaceutiacal compositions, e.g. compositions in the form of tablets, pellets, capsules, microgranules, powders, etc.
Echinacea powder or extract (hereiafter Echfnacea preparation) may be obtained from Echinacea leafes, roots, or whole plants. Examples of Echinacea species that preparations thereof are suitable to serve as binders according to the present invention are those known as Ecl;inacea purpurea, Echinacea angustlfolia, Echinacea pallida, Echinacea paradoxa, Echinacea tennesseensis, Echinacea 1 o sanguinea, Echinacea simulata and Echinacea atrotubens.
Examples of Echinacea preparations are Echinacea angustifoliae herba et radix, Echinacea pallidae herba, Echinacea pallidae radix, Echir..acea purpureae herba, and Echinacea pwpareae redrr.
Thus, the present invention provides, by a first of its aspects, a ls pharlnaceutical composition comprising particulate matter containing at least one pharmaceutically active ingredient and a binder, characterized in that said binder comprises a binding-effective amount of Echinacea preparation.
The term "binding-effectfve amount" should be understood to denote an amount of Echinacea preparation effective in binding or assisting in binding 20 together components of the composition. The binder may consist of Echinacea preparation or may be a mixture of Echinacea preparation and other ingredients, with the Echinacea preparation having a role in binding the compositions' component together. The property of being included in a binding-effective amount is manifested in that when the Echinacea preparation is removed, the composition's 25 other components will not bind to one another at sufficient strength to hold the composition's components together. In the presence of a binding-effective amount of Echinacea preparation, there is a measurable improvement of physical properties such as hardness (in tablets) and of flowability (in powders) in comparison to the same tablets or powders in the absence of binding-effective amount of Echinacea 30 preparation. Typically, the Echinacea preparation will constitute at least about 20 wt%
_ j -of the binding component of the composition, preferably at least about 40 wt%, and particularly preferably at least about 60 wt% and desirably above 80 wt%
of the binding component of the composition The pharmaceutical composition is typically formed into a dosage form such as a tablet or a capsule. At times, the formed pharmaceutical=composition, e.g. h-i the form of small pellets, powder, and the like, may be incorporated into a capsule or a sachet.
The active ingredient may be an analgesic, an antipyretic agent, an anti-inflammatory agent, a vitamin, an expectorant, an antibiotic, etc. These types io of active ingredients are but an example and the invention is not limited thereto. On the contrary, the pharmaceutical compositions of the invention may be used for essentially all types of different active ingredients, which are compatible with the Echinacea preparation. Furthermore, the pharmaceutical composition of the invention is intended for oral administration and thus the active ingredient should be adapted for such form of administration, namely, should be orally bioavailable.
Specific examples of active ingredients are paracetamol, carbocysteine, dextromethorphan, loratadine and vitamin C.
The invention also provides, by another of its aspects, a process for forming a phannaceutical composition, comprising:
(a) preparing a mixture comprising at least one active ingredient and an excipient;
(b) adding a binder to said mixture; and (c) processing said mixture to yield an administration forni, in which form said binder binds together ingredients of the composition;
said process being characterized in that said binder comprises a binding-effective amount of Echinacea preparation and said processing comprises applying conditions in which said preparation binds together ingredients of the composition.
By a still ftwther aspect, the present invention provides a method of administering Echinacea preparation and a pharinaceutically active ingredient to an ;o individual, comprising:
(a) preparing a mixture comprising said active ingredient, an excipient and the Echinacea preparation;
(b) processing the mixture to obtain an administration form, said processing being under conditions such that said preparation bind together all the ingredients in the administration form;
(c) administering said administration form to the individual.
The invention even further provides use of an excipient of Echinacea preparation and an active ingredient to yield a pharmaceutical composition wherein said preparation binds together components of the composition.
In accordance with one aspect of the present invention there is provided a pharmaceutical composition comprising: at least one pharmaceutically active ingredient and at least one excipient, said at least one excipient includes a binder, said binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, and said binder is mixed with the at least one pharmaceutically active ingredient of the composition, to form a solid pharmaceutical composition form wherein the Echinacea extract is blended with said at least one pharmaceutically active ingredient and said pharmaceutical composition is in a solid form adapted for administration.
In accordance with another aspect of the present invention there is provided a process for forming a pharmaceutical composition comprising at least one pharmaceutically active ingredient and at least one excipient, wherein said excipient includes a binder; the process comprising mixing said at least one pharmaceutically active ingredient with said binder, wherein said binder comprises at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, to obtain a blend of said at least one pharmaceutically active ingredient and Echinacea extract; and processing the blend to produce the pharmaceutical composition in a solid form adapted for administration.
In accordance with yet another aspect of the present invention there is provided in a method for producing a pharmaceutical composition in tablet form, an improved method for obtaining harder tablets, the improvement comprising: adding to a 4a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
In accordance with a further aspect of the present invention there is in a method for producing a pharmaceutical composition in powder form, an improved method for obtaining powder with improved flowability, the improvement comprising: adding to a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
In accordance with yet a further aspect of the present invention there is provided an Echinacea extract as a binder for a pharmaceutical composition, wherein said binder comprises at least 2 wt.% of Echinacea extract of said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder.
In accordance with still a further aspect of the present invention there is provided a use of an Echinacea extract as a binder in the manufacture of a pharmaceutical composition, wherein said binder comprises at least 2 wt.% of Echinacea extract of said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder.
The invention will now be illustrated in the following non-lirniting examples.
In accordance with one embodiment of the present invention there is an Echinacea extract as a binder for a pharmaceutical composition.
In accordance with another embodiment of the present invention there is use of an Echinacea extract as a binder in the manufacture of a pharmaceutical composition.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. I shows the size distribution of the particles obtained in example 1.
Fig. 2 shows the size distribution of the particles obtained in example 2.
4b EXAMPLES
In the following example 1 the Echinacea preparation was Echinacea purpurea E, supplied by Phannabeta AG, Switzerland and in examples 2, 3, and 4 the Echinacea preparation was Echinacea Plante Extrait Sec supplied by Martin Bower, France.
Example 1: Preparation of Paracetamol tablets with Echinacea as a single binder.
11.6 g of Echinacea were dissolved in 60 ml of purified water and the solution was poured drop-wise on 215 g of paracetamol and mixed with it manually. The mixture was dried in 45 C (LOD=1.0%). The resulting dry granulate was ground in a 1 mm net. 1 g magnesium stearate and 9.0 g of PrimojeP' were added. The mixture was moistured with a little water and dried (LOD=2.8%). The dried mixture was then pressed to give round tablets of 13 mm diameter, each e I de I. I I I i i x. 1 WO G 3!jfil 4 11 -5 PLTiiL ,r.'Ui;D41s -J-containing 500 mg of paracetamol. The hardness of the tabiets was 44 5 N. The size distribution of the resulting pal -ticles is shown in Figure 1.
Example 2: Preparation of carboeysteiu capsules wlt3n Echinacea as a single binder.
5 g of Echinacea preparation were dissolved in 30 ml water.
187.5 g of carbocystein were mixed with 4 g of AvicelTM
The Echinacea solution was ad,ded to the mixture of the powders and I o manually stirred to granulation. 'I'hegranulate was dried at 40 C
(L{}I3=0.7%). The dry granulate was ground on a 1 mm net and mixed with 7 g AvicelT and 1 g magnesium stearate to give the final blend. The final blend was filled inside hard gelatin capsules of capsule size no. 0, 375 mg active ingredient per capsule.
The particle size distribution of the final blend is shown in Figure 2.
Example 3: Application of dextromethorphan on peRets, using Echinacea as a binder.
8 g of Echinacea were dissolved in 300 ml of purified water, and 4 g of PEG 4000 were added to the solution. 40 g of dextromethorphan HBr were added to the solution to give a dispersion. The dispersion was applied to Neutral pellets No. 20 during heating. 40 g of dextromethyorphan IHBr were suspended in tge alm solution and sprayed on neutral sugar sphere (pellets size 20) using Glatt-Wurster equipment. Coated pelletswere filled inside hard gelatin capsules.
Example 4: Preparation of Loratadine tablets by direct compression with Echirracesa.
10 g of Loratadine were mixed with 25 g of Echinacea. The mixture was 3o sieved on a 50 mesh sieNie. 163 g of Lactose DC were added and mixed. 2 g of magnesium stearate were added and mixed to give the fmal mixture. The final mixture was pressed in a die to give tablets that contained 100 mg and 200 mg active ingredient. The 100 mg tablets had hardness of 99 1 N and the 200 mg tablets had hardness of 85 1 N.
Claims (18)
1. A pharmaceutical composition comprising:
at least one pharmaceutically active ingredient and at least one excipient, said at least one excipient includes a binder, said binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, and said binder is mixed with the at least one pharmaceutically active ingredient of the composition, to form a solid pharmaceutical composition form wherein the Echinacea extract is blended with said at least one pharmaceutically active ingredient and said pharmaceutical composition is in a solid form adapted for administration.
at least one pharmaceutically active ingredient and at least one excipient, said at least one excipient includes a binder, said binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, and said binder is mixed with the at least one pharmaceutically active ingredient of the composition, to form a solid pharmaceutical composition form wherein the Echinacea extract is blended with said at least one pharmaceutically active ingredient and said pharmaceutical composition is in a solid form adapted for administration.
2. A pharmaceutical composition according to claim 1, wherein each of said at least one pharmaceutically active ingredient is selected from the group consisting of analgesic, antipyretic, anti-inflammatory, anti-histaminic, expectorating, and antibiotic agents.
3. A pharmaceutical composition according to Claim 1 or 2, wherein said binder holds said ingredients to yield a dosage form of the at least one pharmaceutically active ingredient.
4. A pharmaceutical composition according to Claim 3, wherein said dosage form is in the form of a tablet.
5. A pharmaceutical composition according to Claim 3, comprising pellets; each of which comprising said active ingredient and said binder.
6. A capsule containing a pharmaceutical composition according to any one of Claims 1, 2, 3 or 5.
7. A pharmaceutical composition according to any one of claims 1 to 6, wherein the active ingredient is paracetamol, carbocysteine, dextromethorphan or loratadine.
8. A pharmaceutical composition according to any one of claims 1 to 7, comprising only one active ingredient.
9. A pharmaceutical composition according to any one of claims 1 to 8, wherein the weight of said Echinacea extract constitutes between about 2% and about 12% of the weight of said pharmaceutical composition.
10. A process for forming a pharmaceutical composition comprising at least one pharmaceutically active ingredient and at least one excipient, wherein said excipient includes a binder; the process comprising mixing said at least one pharmaceutically active ingredient with said binder, wherein said binder comprises at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, to obtain a blend of said at least one pharmaceutically active ingredient and Echinacea extract;
and processing the blend to produce the pharmaceutical composition in a solid form adapted for administration.
and processing the blend to produce the pharmaceutical composition in a solid form adapted for administration.
11. A process according to claim 10, wherein each said pharmaceutically active ingredient is selected from the group consisting of analgesic, antipyretic, anti-inflammatory, anti-histaminic, expectorating, and antibiotic agents.
12. The process of claim 10, wherein said active ingredient is selected from the group consisting of paracetamol, carbocysteine, dextromethorphan, and loratadine.
13. A process according to any one of claims 10 to 12, comprising only one active ingredient.
14. A process according to any one of claims 10 to 13, wherein the weight of said Echinacea extract constitutes between about 2% and about 12% of the weight of said pharmaceutical composition.
15. In a method for producing a pharmaceutical composition in tablet form, an improved method for obtaining harder tablets, the improvement comprising:
adding to a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
adding to a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
16. In a method for producing a pharmaceutical composition in powder form, an improved method for obtaining powder with improved flowability, the improvement comprising: adding to a composition comprising at least one pharmaceutically active ingredient a binder, the binder comprising at least 2 wt.% of Echinacea extract in said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder, wherein said Echinacea extract is blended with said at least one pharmaceutically active ingredient.
17. An Echinacea extract as a binder for a pharmaceutical composition, wherein said binder comprises at least 2 wt.% of Echinacea extract of said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder.
18. Use of an Echinacea extract as a binder in the manufacture of a pharmaceutical composition, wherein said binder comprises at least 2 wt.% of Echinacea extract of said pharmaceutical composition and at least 20 wt.% Echinacea extract in the binder.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL131317A IL131317A (en) | 1999-08-09 | 1999-08-09 | Binder for pharmaceutical compositions |
| IL131317 | 1999-08-09 | ||
| PCT/IL2000/000412 WO2001010415A1 (en) | 1999-08-09 | 2000-07-13 | A binder for pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2378987A1 CA2378987A1 (en) | 2001-02-15 |
| CA2378987C true CA2378987C (en) | 2008-05-06 |
Family
ID=11073130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002378987A Expired - Fee Related CA2378987C (en) | 1999-08-09 | 2000-07-13 | A binder for pharmaceutical compositions |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1200069A1 (en) |
| AU (1) | AU5842800A (en) |
| CA (1) | CA2378987C (en) |
| IL (1) | IL131317A (en) |
| WO (1) | WO2001010415A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN192160B (en) * | 2000-07-17 | 2004-02-28 | Ranbaxy Lab |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT385654B (en) * | 1984-09-04 | 1988-05-10 | Arcana Chem Pharm | Process for the production of oil-containing preparations in granule form for oral administration |
| DK0620727T3 (en) * | 1992-01-17 | 1997-05-26 | Alfatec Pharma Gmbh | |
| ATE204159T1 (en) * | 1995-05-17 | 2001-09-15 | Peter Greither | METHOD FOR PRODUCING AN EFFORTABLE PREPARATION AND EFFORTABLE PREPARATION |
-
1999
- 1999-08-09 IL IL131317A patent/IL131317A/en not_active IP Right Cessation
-
2000
- 2000-07-13 AU AU58428/00A patent/AU5842800A/en not_active Abandoned
- 2000-07-13 WO PCT/IL2000/000412 patent/WO2001010415A1/en not_active Application Discontinuation
- 2000-07-13 CA CA002378987A patent/CA2378987C/en not_active Expired - Fee Related
- 2000-07-13 EP EP00944197A patent/EP1200069A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU5842800A (en) | 2001-03-05 |
| IL131317A (en) | 2006-08-01 |
| CA2378987A1 (en) | 2001-02-15 |
| EP1200069A1 (en) | 2002-05-02 |
| WO2001010415A1 (en) | 2001-02-15 |
| IL131317A0 (en) | 2001-01-28 |
| WO2001010415B1 (en) | 2001-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3647897B2 (en) | Sustained release unit dosage form | |
| KR0166064B1 (en) | Rotogranulations and taste masking coatings for peparation of chewable pharmaceutical tablets | |
| JP3045924B2 (en) | Controlled release oral drug formulations | |
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| CA2888278A1 (en) | Oral drug delivery formulations | |
| WO1999016448A1 (en) | Sustained-release theophylline tablet | |
| JP2007530684A (en) | Tamper-resistant dosage form containing adsorbent and adverse agent | |
| JP2009528329A (en) | Crush-resistant tablets to prevent accidental misuse and illegal diversion | |
| TWI374035B (en) | Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof | |
| JP2001172201A (en) | Use of film coating for masking the taste for oral administration, oral administration form and production thereof | |
| JPH05200099A (en) | Tablet stable mechanically and decomposa- ble easily as produced from fine particle molded previously containing active component | |
| KR100369874B1 (en) | Antacid compositions and pharmaceutical compositions | |
| CN108201534A (en) | A kind of Rui Kapabu takes orally sustained and controlled release medicament composition and application thereof | |
| WO2013082706A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
| JP4856843B2 (en) | New fenofibrate tablets | |
| CN102451162A (en) | Olanzapine medicine absorbed through oral mucosa | |
| JP2007055924A (en) | Solid preparation containing ibuprofen and ambroxol hydrochloride | |
| CN108201535A (en) | A kind of Wei Lipani sustained and controlled release medicaments composition and application thereof | |
| JP5347092B2 (en) | Andrographis extract formulation | |
| CA2378987C (en) | A binder for pharmaceutical compositions | |
| KR101168189B1 (en) | Process for producing coated preparation having relieved unpleasantness | |
| JPH08310969A (en) | Solid pharmaceutical composition and its preparation | |
| JP2013023463A (en) | Method for producing physiologically active substance-containing granule | |
| CN101385733B (en) | Composite glycyrrhizin sustained release preparation | |
| CN105407876A (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |